Beta Bionics, Inc. (BBNX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Beta Bionics, Inc. (BBNX) Healthcare & Pipeline Overview

Beta Bionics, Inc. develops and commercializes medical devices for diabetes management, primarily the iLet Bionic Pancreas, an insulin delivery system for type 1 diabetes. With a focus on automated insulin delivery, the company aims to improve the health and quality of life for insulin-requiring individuals, competing in the medical equipment and services sector.

What Is the Investment Thesis for BBNX?

Beta Bionics presents a notable research candidate within the diabetes management space, driven by its innovative iLet Bionic Pancreas system. The company's focus on automated insulin delivery addresses a significant unmet need for individuals with type 1 diabetes, potentially leading to strong market adoption. Key value drivers include the expansion of iLet's user base, successful development and commercialization of pipeline products like the Patch Pump and Bihormonal iLet, and strategic partnerships to enhance its technology and market reach. The company's gross margin of 57.2% indicates a solid foundation for profitability as sales scale. However, potential risks include competition from established players, regulatory hurdles, and the company's current negative profit margin of -60.3%, indicating a need for efficient cost management as it grows.

Based on FMP financials and quantitative analysis

BBNX Key Highlights

Market Cap of $876M reflects investor valuation of Beta Bionics' potential in the diabetes management market.

• Gross Margin of 57.2% indicates strong pricing power and efficient production costs for the iLet Bionic Pancreas.
• Profit Margin of -60.3% highlights the company's current focus on growth and investment in R&D and commercialization.
• Beta of 5.06 suggests high volatility relative to the market, reflecting the growth stage of the company.
• No Dividend Yield indicates that the company is reinvesting earnings for future growth.

Who Are BBNX's Competitors?

BBNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BBNX's Key Strengths?

Innovative iLet Bionic Pancreas technology.

• Strategic partnerships with Xeris and Abbott.
• Focus on automated insulin delivery.
• Strong gross margin of 57.2%.

What Are BBNX's Weaknesses?

Negative profit margin of -60.3%.

• Limited product portfolio concentrated on diabetes management.
• Reliance on regulatory approvals for new products.
• High beta of 5.06 indicating high volatility.

What Could Drive BBNX Stock Higher?

Regulatory approval and launch of the Patch Pump.

• Expansion of iLet Bionic Pancreas sales and market share.
• Progress in the development of the Bihormonal iLet.
• Strategic partnerships and collaborations to enhance product offerings.

What Are the Key Risks for BBNX?

Negative return on equity (-23.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Regulatory hurdles and delays in product approvals.
• Reimbursement challenges from healthcare payers.
• Negative profit margin requiring efficient cost management.
• High beta indicating high stock price volatility.

What Are the Growth Opportunities for BBNX?

• Expansion of iLet Bionic Pancreas User Base: The primary growth opportunity lies in expanding the user base of the iLet Bionic Pancreas. By increasing awareness, improving user experience, and securing favorable reimbursement policies, Beta Bionics can capture a larger share of this market. Timeline: Ongoing.
• Development and Commercialization of Patch Pump: The development and commercialization of the Patch Pump represent another significant growth opportunity. This tubeless insulin pump offers increased convenience and discretion for users, potentially attracting a new segment of the market. Successful launch and adoption of the Patch Pump could drive revenue growth and enhance Beta Bionics' product portfolio. Timeline: Within the next 2-3 years.
• Bihormonal iLet Development: The Bihormonal iLet, which combines automated insulin and glucagon delivery, holds promise for improved glucose control and reduced risk of hypoglycemia. Successful development and regulatory approval of this device could establish Beta Bionics as a leader in advanced diabetes management solutions. The market for bihormonal therapies is nascent but expected to grow as the benefits become more evident. Timeline: Within the next 3-5 years.
• Expansion into Type 2 Diabetes Market: Extending the iLet technology to individuals with insulin-dependent type 2 diabetes represents a substantial growth opportunity. The type 2 diabetes population is significantly larger than the type 1 population, offering a broader market for Beta Bionics' products. Adapting the iLet system for type 2 diabetes could drive significant revenue growth. Timeline: Within the next 3-5 years.
• Strategic Partnerships and Collaborations: Continued strategic partnerships and collaborations with companies like Xeris and Abbott can accelerate product development, expand market reach, and enhance Beta Bionics' technology platform. These partnerships can provide access to complementary technologies, distribution channels, and expertise, driving long-term growth and innovation. Timeline: Ongoing.

What Are BBNX's Competitive Advantages?

• Proprietary iLet Bionic Pancreas technology with automated insulin delivery.
• Strategic partnerships with Xeris and Abbott.
• Focus on innovation in diabetes management solutions.
• Potential for expansion into the type 2 diabetes market.

What Does BBNX Do?

Beta Bionics, Inc., founded in 2015 and based in Irvine, California, is a commercial-stage medical device company dedicated to designing, developing, and commercializing innovative solutions for individuals with diabetes. The company's flagship product is the iLet Bionic Pancreas, an insulin delivery device approved for use in adults and children six years of age and older with type 1 diabetes. This system automates insulin delivery, aiming to simplify diabetes management and improve glycemic control. Beyond the iLet Bionic Pancreas, Beta Bionics is actively developing other products, including the Patch Pump, a discreet, tubeless insulin pump designed for ease of use. The company is also working on the Bihormonal iLet, which combines automated delivery of both insulin and glucagon, potentially offering more comprehensive glucose management. Additionally, Beta Bionics is exploring the application of its iLet technology for individuals with insulin-dependent type 2 diabetes, expanding its potential market reach. Beta Bionics has established strategic collaborations to enhance its product offerings, including agreements with Xeris Pharmaceuticals, Inc. to develop and commercialize a pump-compatible glucagon formulation, and with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.

What Products and Services Does BBNX Offer?

• Develop and commercialize the iLet Bionic Pancreas, an automated insulin delivery system.
• Offer a solution for managing type 1 diabetes in adults and children.
• Develop the Patch Pump, a tubeless insulin pump for convenient insulin delivery.
• Work on the Bihormonal iLet, combining insulin and glucagon delivery for enhanced glucose control.
• Collaborate with Xeris Pharmaceuticals to develop a pump-compatible glucagon formulation.
• Partner with Abbott Diabetes Care to develop an automated insulin delivery system.
• Focus on improving the health and quality of life for people with diabetes.

How Does BBNX Make Money?

• Sales of the iLet Bionic Pancreas device.
• Recurring revenue from consumables, such as insulin cartridges.
• Partnerships and collaborations with pharmaceutical and medical device companies.
• Future revenue from the Patch Pump and Bihormonal iLet devices.

What Industry Does BBNX Operate In?

Beta Bionics operates in the medical device industry, specifically within the diabetes management sector. The market for diabetes care is substantial and growing, driven by the increasing prevalence of diabetes globally. The competitive landscape includes established medical device companies and emerging players focused on innovative technologies like continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems. Beta Bionics' iLet Bionic Pancreas positions it within the AID segment, which is expected to see significant growth as users seek more convenient and effective diabetes management solutions.

Who Are BBNX's Key Customers?

• Individuals with type 1 diabetes.
• Adults and children (6 years and older) requiring insulin therapy.
• Healthcare providers and diabetes clinics.
• Hospitals and endocrinology centers.

Over the past six months, Beta Bionics, Inc. insiders filed 30 SEC Form 4 transactions — 20 sales and 10 purchases. On net that is roughly 35K shares acquired (about $937K) — insiders putting money in tends to read as conviction.

Wall Street analysts project Beta Bionics, Inc. revenue of about $133.8M for fiscal 2026, with EPS near $-2.14. The estimate reflects 8 contributing analysts.

Beta Bionics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.67 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Beta Bionics, Inc. stands at -23.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.9%, the inverse of the P/E and a quick read on earnings relative to price.

Beta Bionics, Inc. (BBNX) Valuation Context

Valued at $876M, BBNX is classified as a small-cap stock. Relative to its peer group, BBNX's quantitative score of 27/100 is below the peer average of 64/100.

BBNX Revenue & Earnings Trend

In Q2 2026, BBNX generated $32.0M in top-line revenue, marking a sequential increase of 15.9%. The company recorded a net loss of $23.4M, with diluted EPS of $-0.53. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BBNX averaged $-0.42 in diluted EPS.

Company Profile

Beta Bionics, Inc. operates in the Medical - Equipment & Services industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Sean T. Saint. BBNX has traded publicly since 2025.

BBNX Financials

BBNX Latest News

BBNX Analyst Consensus

BBNX MoonshotScore

BBNX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources